| human | Q5 |
| P227 | GND ID | 1220121037 |
| P269 | IdRef ID | 083251626 |
| P496 | ORCID iD | 0000-0002-3050-0140 |
| P1053 | ResearcherID | P-8872-2014 |
| P1153 | Scopus author ID | 35468172900 |
| P214 | VIAF ID | 173262075 |
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q73329209 | 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia |
| Q77838196 | 14q32 chromosomal translocations: a hallmark of plasma cell dyscrasias? |
| Q46339067 | 8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma. |
| Q37325007 | A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma |
| Q41009823 | A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. |
| Q61905635 | A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis |
| Q73062440 | A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease |
| Q42563529 | Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy |
| Q82564216 | Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial |
| Q84715517 | Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials |
| Q57785893 | Activating Ras mutations in patients with plasma-cell disorders: a reappraisal |
| Q71839752 | Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas |
| Q46614351 | Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acu |
| Q39210735 | Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients |
| Q74213158 | Amplification of AML1 gene is present in childhood acute lymphoblastic leukemia but not in adult, and is not associated with AML1 gene mutation |
| Q73720246 | Amplification of band q22 of chromosome 21, including AML1, in older children with acute lymphoblastic leukemia: an emerging molecular cytogenetic subgroup |
| Q38736404 | Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma. |
| Q64931827 | Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. |
| Q37197900 | BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice |
| Q47307819 | BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee |
| Q39402566 | Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. |
| Q46265856 | Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. |
| Q43250016 | Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). |
| Q42965343 | Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). |
| Q42914716 | Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. |
| Q84783323 | Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma |
| Q40781792 | Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. |
| Q52018083 | CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. |
| Q81224742 | CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target |
| Q63347026 | CD4+, CD56+ DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogenetique Hematologique |
| Q40810558 | Ca2+-sensitive cytosolic nucleases prevent efficient delivery to the nucleus of injected plasmids. |
| Q57784502 | Carfilzomib Weekly 20/56mg/m , Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma |
| Q37228327 | Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. |
| Q50098115 | Circulating exosomal microRNA as biomarkers in mutiple myeloma |
| Q38657175 | Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. |
| Q30571858 | Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project |
| Q48484979 | Comparative genomic hybridization detects specific cytogenetic abnormalities in pediatric ependymomas and choroid plexus papillomas. |
| Q38398899 | Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma |
| Q52528580 | Construction of a 780-kb PAC, BAC, and cosmid contig encompassing the minimal critical deletion involved in B cell chronic lymphocytic leukemia at 13q14.3. |
| Q62059264 | Cyclin D1 expression in patients with multiple myeloma |
| Q58051878 | Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience |
| Q59797151 | Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR |
| Q59797112 | Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX |
| Q43989451 | Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. |
| Q24671504 | Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization |
| Q42915044 | Difficulties in immunofixation analysis: a concordance study on the IFM 2007-02 trial. |
| Q52725904 | Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. |
| Q44962377 | Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. |
| Q48193638 | Expressed fusion gene landscape and its impact in multiple myeloma. |
| Q52663535 | Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC. |
| Q73589839 | Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia |
| Q55119916 | Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. |
| Q43847809 | Gene Expression Profiles in Myeloma: Ready for the Real World? |
| Q34345502 | Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. |
| Q40209753 | Gene signature combinations improve prognostic stratification of multiple myeloma patients. |
| Q53243787 | Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. |
| Q35945858 | Genetic heterogeneity in multiple myeloma. |
| Q35197437 | Genetics of multiple myeloma: another heterogeneity level? |
| Q58721686 | Genomic patterns of progression in smoldering multiple myeloma |
| Q38905598 | Genomics of Multiple Myeloma. |
| Q50224356 | Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. |
| Q38373226 | Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria |
| Q80599629 | Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials |
| Q57785902 | High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis |
| Q38131380 | IMWG consensus on risk stratification in multiple myeloma |
| Q39309897 | Identification of miRSNPs associated with the risk of multiple myeloma. |
| Q58792995 | Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma |
| Q44818652 | IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma. |
| Q40678259 | IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia. |
| Q34241661 | International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. |
| Q90764097 | Introduction to a review series on advances in multiple myeloma |
| Q78800404 | Is t(14;18)(q32;q21) a constant finding in follicular lymphoma? An interphase FISH study on 63 patients |
| Q50062890 | Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. |
| Q82200791 | Lack of CD27 in myeloma delineates different presentation and outcome |
| Q74677662 | Large deletions 5' to the ETO breakpoint are recurrent events in patients with t(8;21) acute myeloid leukemia |
| Q58415969 | Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma |
| Q41756273 | Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma |
| Q38852886 | Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. |
| Q75235838 | Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level |
| Q88636701 | Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma |
| Q47826998 | Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. |
| Q46317190 | Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. |
| Q79696686 | Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma |
| Q80011690 | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma |
| Q37970946 | Management of treatment-emergent peripheral neuropathy in multiple myeloma. |
| Q79845337 | Mature B-cell lymphoblastic leukemia with MLL rearrangement: an uncommon and distinct subset of childhood acute leukemia |
| Q40420617 | Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. |
| Q56563817 | MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma |
| Q88108634 | Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy |
| Q57151125 | Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma |
| Q34111475 | Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management |
| Q89082159 | Multiple myeloma clonal evolution in homogeneously treated patients |
| Q56959286 | Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q57785739 | Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow |
| Q60035759 | N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique |
| Q27004421 | New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) |
| Q38764731 | Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles. |
| Q90776894 | Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma |
| Q38739689 | Nucleotide excision repair is a potential therapeutic target in multiple myeloma. |
| Q77725517 | Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation |
| Q47153439 | Optimizing therapy for del(17p) multiple myeloma. |
| Q34338377 | Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. |
| Q82737612 | Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease |
| Q42940540 | Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial |
| Q80989679 | Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma |
| Q58051897 | Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M |
| Q52801394 | Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. |
| Q38715962 | Prognostic role of circulating exosomal miRNAs in multiple myeloma |
| Q36525224 | Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients. |
| Q82971569 | Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study |
| Q88470620 | Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 |
| Q38870324 | Radiolabelling rituximab with (99m)Tc in three steps procedure |
| Q35767684 | Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization. |
| Q79839224 | Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implications |
| Q74605768 | Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy |
| Q91546774 | Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside |
| Q79702602 | Rituximab in CD20 positive multiple myeloma |
| Q71041196 | Rothmund-Thomson syndrome and osteosarcoma |
| Q53203181 | Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma. |
| Q48250873 | Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma. |
| Q79756999 | Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases |
| Q43081275 | Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. |
| Q79910025 | Stem cell transplantation in multiple myeloma |
| Q89479926 | TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma |
| Q38692511 | The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications |
| Q46892396 | The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. |
| Q33841474 | The dChip survival analysis module for microarray data. |
| Q59413119 | Total Soluble HLA Class I and Soluble HLA-G in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance |
| Q78410075 | Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants |
| Q45738627 | Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? |
| Q37949201 | Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. |
| Q37990030 | Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. |
| Q93078751 | Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14) |
| Q80458068 | [Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival] |
| Q80351291 | [Malignant transformation of monoclonal gammopathy of undetermined significance] |
| Q79087985 | t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma |
Search more.